Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Menter

Showing results (201-210 of 298) with videos related to

Pageof 30
Sort By:
Journal of Drugs in Dermatology : JDD|February 5, 2013
Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trialAlan Menter, Linda Stein Gold, Michael Bukhalo, et al.
Expert Opinion on Biological Therapy|December 15, 2020
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO studyAlan Menter, Petr Arenberger, Sigrid Balser, et al.
Journal of Drugs in Dermatology : JDD|August 27, 2020
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)M Alan Menter, Nehal N Mehta, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|February 21, 2006
Relapse, rebound, and psoriasis adverse events: an advisory group reportWayne Carey, Scott Glazer, Alice B Gottlieb, et al.
Journal of Drugs in Dermatology : JDD|August 13, 2015
Reproducible Novel Transcriptional Differences Between Psoriatic Lesional and Non-Lesional Skin Show Increased Inflammation and MetabolismDaniel J Aires, Graham Rockwell, Alan Menter, et al.
Journal of the American Academy of Dermatology|April 1, 2015
Genital psoriasis is associated with significant impairment in quality of life and sexual functioningCaitriona Ryan, Muriel Sadlier, Edward De Vol, et al.
The Journal of Dermatological Treatment|July 4, 2019
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasisBoni Elewski, Alan Menter, Jeffrey Crowley, et al.
Journal of Drugs in Dermatology : JDD|January 14, 2009
Adverse drug events in infliximab-treated patients compared with the general and psoriasis populationsAlan Menter, Kristian Reich, Alice B Gottlieb, et al.
Physiological Genomics|March 20, 2003
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide arrayXianghong Zhou, James G Krueger, Ming-Chih J Kao, et al.
Cutis|November 24, 2011
An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasisCharles P Hudson, Steven Kempers, Alan Menter, et al.
Pageof 30

Showing results (201-210 of 298) with videos related to

Sort By:
Pageof 30
Journal of Drugs in Dermatology : JDD|February 5, 2013
Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trialAlan Menter, Linda Stein Gold, Michael Bukhalo, et al.
Expert Opinion on Biological Therapy|December 15, 2020
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO studyAlan Menter, Petr Arenberger, Sigrid Balser, et al.
Journal of Drugs in Dermatology : JDD|August 27, 2020
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)M Alan Menter, Nehal N Mehta, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|February 21, 2006
Relapse, rebound, and psoriasis adverse events: an advisory group reportWayne Carey, Scott Glazer, Alice B Gottlieb, et al.
Journal of Drugs in Dermatology : JDD|August 13, 2015
Reproducible Novel Transcriptional Differences Between Psoriatic Lesional and Non-Lesional Skin Show Increased Inflammation and MetabolismDaniel J Aires, Graham Rockwell, Alan Menter, et al.
Journal of the American Academy of Dermatology|April 1, 2015
Genital psoriasis is associated with significant impairment in quality of life and sexual functioningCaitriona Ryan, Muriel Sadlier, Edward De Vol, et al.
The Journal of Dermatological Treatment|July 4, 2019
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasisBoni Elewski, Alan Menter, Jeffrey Crowley, et al.
Journal of Drugs in Dermatology : JDD|January 14, 2009
Adverse drug events in infliximab-treated patients compared with the general and psoriasis populationsAlan Menter, Kristian Reich, Alice B Gottlieb, et al.
Physiological Genomics|March 20, 2003
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide arrayXianghong Zhou, James G Krueger, Ming-Chih J Kao, et al.
Cutis|November 24, 2011
An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasisCharles P Hudson, Steven Kempers, Alan Menter, et al.
Pageof 30